<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T05:10:33Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4720584" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4720584</identifier>
        <datestamp>2016-05-18</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">8702459</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">2334</journal-id>
              <journal-id journal-id-type="nlm-ta">Bone Marrow Transplant</journal-id>
              <journal-id journal-id-type="iso-abbrev">Bone Marrow Transplant.</journal-id>
              <journal-title-group>
                <journal-title>Bone marrow transplantation</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0268-3369</issn>
              <issn pub-type="epub">1476-5365</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4720584</article-id>
              <article-id pub-id-type="pmcid">PMC4720584</article-id>
              <article-id pub-id-type="pmc-uid">4720584</article-id>
              <article-id pub-id-type="pmid">26191952</article-id>
              <article-id pub-id-type="pmid">26191952</article-id>
              <article-id pub-id-type="doi">10.1038/bmt.2015.170</article-id>
              <article-id pub-id-type="manuscript">nihpa699693</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title><italic>FLT3</italic> mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Song</surname>
                    <given-names>Yeohan</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Magenau</surname>
                    <given-names>John</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Yumeng</given-names>
                  </name>
                  <xref ref-type="aff" rid="A5">5</xref>
                  <xref ref-type="aff" rid="A6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Braun</surname>
                    <given-names>Thomas</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="A5">5</xref>
                  <xref ref-type="aff" rid="A6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chang</surname>
                    <given-names>Lawrence</given-names>
                  </name>
                  <degrees>M.D., M.P.H.</degrees>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bixby</surname>
                    <given-names>Dale</given-names>
                  </name>
                  <degrees>M.D., Ph.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hanauer</surname>
                    <given-names>David A.</given-names>
                  </name>
                  <degrees>M.D., M.S.</degrees>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A6">6</xref>
                  <xref ref-type="aff" rid="A8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chughtai</surname>
                    <given-names>Komal A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gatza</surname>
                    <given-names>Erin</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Couriel</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Goldstein</surname>
                    <given-names>Steven</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pawarode</surname>
                    <given-names>Attaphol</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Reddy</surname>
                    <given-names>Pavan</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Riwes</surname>
                    <given-names>Mary</given-names>
                  </name>
                  <degrees>D.O.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Connelly</surname>
                    <given-names>James</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harris</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kitko</surname>
                    <given-names>Carrie</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Levine</surname>
                    <given-names>John</given-names>
                  </name>
                  <degrees>M.D., M.S.</degrees>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yanik</surname>
                    <given-names>Greg</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Parkin</surname>
                    <given-names>Brian</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Choi</surname>
                    <given-names>Sung Won</given-names>
                  </name>
                  <degrees>M.D., M.S.</degrees>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A4">4</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>1</label>University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.</aff>
              <aff id="A2"><label>2</label>Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.</aff>
              <aff id="A3"><label>3</label>Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA.</aff>
              <aff id="A4"><label>4</label>Hematological Malignancies and Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI, USA.</aff>
              <aff id="A5"><label>5</label>School of Public Health, University of Michigan, Ann Arbor, MI, USA.</aff>
              <aff id="A6"><label>6</label>Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.</aff>
              <aff id="A7"><label>7</label>Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.</aff>
              <aff id="A8"><label>8</label>Bioinformatics Core, University of Michigan, Ann Arbor, MI, USA.</aff>
              <author-notes>
                <corresp id="CR1">Corresponding Author: Sung Won Choi, M.D., M.S. Department of Pediatrics and Communicable Diseases Blood and Marrow Transplantation Program 1500 E. Medical Center Dr. D4118 Medical Professional Building, SPC 5718 Ann Arbor, MI 48109-5718 Phone: 734-615-5707 Fax: 734-615-0464 <email>sungchoi@med.umich.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>13</day>
                <month>6</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>7</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>4</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>18</day>
                <month>5</month>
                <year>2016</year>
              </pub-date>
              <volume>51</volume>
              <issue>4</issue>
              <fpage>511</fpage>
              <lpage>520</lpage>
              <!--elocation-id from pubmed: 10.1038/bmt.2015.170-->
              <permissions>
                <license xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">
                  <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p>
                </license>
              </permissions>
              <abstract>
                <p id="P1">Allogeneic HCT has been increasingly used in the setting of <italic>FLT3</italic> mutated AML. However, its role in conferring durable relapse-free intervals remains in question. Herein, we sought to investigate <italic>FLT3</italic> mutational status on transplant outcomes. We conducted a retrospective cohort study of 262 consecutive AML patients who underwent first-time allogeneic HCT (2008-2014), of whom 171 had undergone <italic>FLT3</italic>-ITD mutational testing. <italic>FLT3</italic> mutated AML was associated with nearly twice the relapse risk (RR) compared with those without <italic>FLT3</italic> mutation 3 years post-HCT (63% vs. 37%, <italic>P</italic>&lt;0.001), and with a shorter median time to relapse (100 vs. 121 days). <italic>FLT3</italic> mutational status remained significantly associated with this outcome after controlling for patient, disease, and transplant-related risk factors (<italic>P</italic>&lt;0.05). Multivariate analysis showed a significant association of <italic>FLT3</italic> mutation with increased 3-year RR (HR 3.63, 95% CI: 2.13, 6.19, <italic>P</italic>&lt;0.001), and inferior disease-free survival (HR 2.05, 95% CI: 1.29, 3.27, <italic>P</italic>&lt;0.01) and overall survival (HR 1.92, 95% CI: 1.14, 3.24, <italic>P</italic>&lt;0.05). These data demonstrate high risk of early relapse after allogeneic HCT for <italic>FLT3</italic> mutated AML that translates into adverse disease-free and overall survival outcomes. Additional targeted and coordinated interventions are needed to maintain durable remission after allogeneic HCT in this high-risk population.</p>
              </abstract>
              <kwd-group>
                <kwd>Acute myeloid leukemia</kwd>
                <kwd><italic>FLT3</italic> mutation</kwd>
                <kwd>
                  <italic>FMS-like tyrosine kinase-3</italic>
                </kwd>
                <kwd>Allogeneic hematopoietic cell transplantation</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="S1">
              <title>INTRODUCTION</title>
              <p id="P2">Acute myeloid leukemia (AML) is a genetically heterogeneous disease.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Acquired somatic mutations in the <italic>FMS-like tyrosine kinase-3</italic> (<italic>FLT3</italic>) gene occur in up to 20% to 30% of AML patients who carry the internal tandem duplication (ITD) mutation.<sup><xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R4" ref-type="bibr">4</xref></sup>
<italic>FLT3-</italic>ITD has been characterized as a gain-of-function mutation with constitutive activation of receptor tyrosine kinase FLT3.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> This alteration has been associated with adverse prognosis in both pediatric and adult AML patients.<sup><xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R6" ref-type="bibr">6</xref></sup></p>
              <p id="P3">Allogeneic hematopoietic cell transplantation (HCT) is an important treatment option for patients with AML.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Unfortunately, disease recurrence and transplant-related toxicity remain the major causes of treatment failure.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> Accordingly, the value of allogeneic HCT in conferring durable long-term remission free intervals continues to be an important consideration, particularly in patients with <italic>FLT3</italic> gene mutation.</p>
              <p id="P4"><italic>FLT3</italic> mutation as an independent risk factor for allogeneic transplant outcomes has previously been explored by several groups through single institution and multi-center registry studies, with inconsistent reports depending on the study population.<sup><xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R31" ref-type="bibr">31</xref></sup> Unfortunately, many of these studies have been restricted to cytogenetically normal AML, small sample sizes, or specific conditioning or donor types, thereby limiting the generalizability of the findings. While allogeneic HCT with the best available donor has become widely adopted as an important therapeutic option in AML patients with <italic>FLT3</italic> mutation who achieve first complete remission (CR1), there may be additional patient, disease, or transplant-specific variables that increase relapse hazards.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> Therefore, in the present study, we investigated the impact of <italic>FLT3</italic> mutational AML on relapse risk (RR), non-relapse mortality (NRM), disease-free survival (DFS), and overall survival outcomes following allogeneic HCT at a single institution between 2008 and 2014. The study design included a retrospective cohort analysis and detailed characterization of patient, disease, and transplant-specific factors by <italic>FLT3</italic> mutational status (positive <italic>vs.</italic> negative).</p>
            </sec>
            <sec sec-type="methods" id="S2">
              <title>PATIENTS AND METHODS</title>
              <sec id="S3">
                <title>Literature review</title>
                <p id="P5">As the focus of this paper was on <italic>FLT3</italic> mutational AML in allogeneic HCT, we conducted a literature search in PubMed/MEDLINE. The search was performed in January 2015 and was restricted to studies published in English within the last 20 years (1995–2015). Three MeSH terms, ‘transplantation,’ ‘<italic>FLT3</italic>,’ and ‘acute myelogenous leukemia’ were used in the search, in addition to various combinations of ‘HCT,’ ‘FMS-like tyrosine kinase 3,’ ‘acute myeloid leukemia,’ and ‘AML.’ The initial search resulted in a total of 300 articles. Two co-authors (YS and SWC) screened a random half set of the abstracts; 277 were determined as not meeting the inclusion criteria. Both authors read the full text of the remaining 23 papers. Each of these papers was reviewed in depth, with key outcomes summarized in <xref ref-type="supplementary-material" rid="SD1">Supplemental Table S1</xref>.</p>
              </sec>
              <sec id="S4">
                <title>Study design</title>
                <p id="P6">A retrospective cohort study was conducted on 262 pediatric and adult AML patients undergoing first-time allogeneic HCT between January 2008 and July 2014. The study was approved by the University of Michigan Institutional Review Board (IRBMED# HUM00095617). Informed consents were obtained from all subjects and data were collected under the IRBMED-approved protocol (IRBMED # HUM43287). Routine <italic>FLT3</italic> mutational testing for AML began in 2008 at the University of Michigan. Twenty-three patients who either had <italic>FLT3</italic>-TKD mutation without <italic>FLT3</italic>-ITD or who received umbilical cord blood transplantation were excluded from the study to reduce potential confounding. An additional 65 patients who did not undergo <italic>FLT3</italic> mutational testing were excluded from the analysis. Details of their patient, disease, and transplant-related characteristics and outcomes are provided in <xref ref-type="supplementary-material" rid="SD1">Supplemental Tables S2–S4</xref>. The total study population was 171 patients with known <italic>FLT3</italic> mutational status (positive <italic>vs.</italic> negative). Cytogenetic and molecular testing (<italic>FLT3</italic> and <italic>NPM1</italic>) was performed at the University of Michigan or at referring institutions.</p>
                <p id="P7">Data abstraction of patient, disease, and transplant-related variables was performed through manual chart review of the Electronic Medical Record system (Careweb and MiChart/EPIC), supported by the University of Michigan Electronic Medical Record Search Engine (EMERSE). EMERSE is designed to comprehensively search all institutional clinical documents using specified search terms and queries.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Documents screened by EMERSE were examined in further detail for relevant study data. Outcomes of the study included RR, graft-versus-host disease (GVHD), NRM, DFS, and overall survival.</p>
              </sec>
              <sec id="S5">
                <title>Patient, disease, and transplant-related characteristics</title>
                <p id="P8">Patient characteristics included age, gender, race, ethnicity, and body mass index (BMI) at the time of allogeneic HCT. A hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score was calculated using documented clinical and laboratory data for each patient in the study, as previously described.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> Disease features included white blood cell (WBC) count at diagnosis, Center for International Blood and Marrow Transplant Research (CIBMTR) cytogenetic risk based on karyotype at diagnosis (noting the presence or absence of complex cytogenetics [≥3 abnormalities]),<sup><xref rid="R34" ref-type="bibr">34</xref></sup>
<italic>NPM1</italic> mutational status, antecedent myelodysplastic syndrome (MDS) or myeloproliferative disorder, and therapy-related AML. Morphologic status at transplant, defined as persistent disease (≥5% blasts) <italic>vs</italic>. complete remission (&lt;5% blasts), and cytogenetic remission status at transplant, defined as normal karyotype without clonal abnormalities, were also collected. Time from diagnosis to transplantation (infusion of allogeneic hematopoietic cells) was recorded (≥ <italic>vs</italic>. &lt;180 days).</p>
                <p id="P9">Transplant-related characteristics included number of pre-transplant chemotherapy cycles (induction and consolidation), conditioning intensity (myeloablative or reduced), use of thymoglobulin or alemtuzumab, total body irradiation (≥1200 cGy), stem cell source (bone marrow or peripheral blood), donor-recipient characteristics (gender, related or unrelated, human leukocyte antigen [HLA] matched [8/8] or mismatched [7/8], ABO and Rh blood type, and cytomegalovirus status), number of CD34+ cells transfused, and length of hospital stay. Additional characteristics included GVHD prophylaxis (calcineurin inhibitor [CNI]-methotrexate or CNI-mycophenolate mofetil) and time to neutrophil engraftment (defined as the first of three consecutive days with absolute neutrophil count [ANC] ≥500/mm<sup>3</sup>).</p>
              </sec>
              <sec id="S6">
                <title>Statistical analysis</title>
                <p id="P10">Statistical analyses were performed using R 3.02 (GNU General Public License) with α=0.05 defining the level of statistical significance (two-sided). Summary data were calculated for patient, disease, and transplant-related variables, with medians and ranges determined for continuous variables and counts and percentages calculated for categorical variables. The cohort was then sub-divided into two groups based on their <italic>FLT3</italic> mutational status, and statistically significant differences between these groups were assessed using the Kruskal-Wallis test for continuous variables and the χ<sup>2</sup> test of association for categorical variables. The Fine-Gray method<sup><xref rid="R35" ref-type="bibr">35</xref></sup> was used to determine cumulative incidences with competing risks, which were then compared using the K-sample tests described by Gray.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> The Kaplan-Meier method was used to compute overall survival.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> Univariate regression methods (competing risks regression for RR, acute and chronic GVHD and NRM, and Cox regression for DFS and overall survival) were used to model the marginal associations of <italic>FLT3</italic> mutational status and other patient, disease, and transplant-related variables with clinical outcomes. Bivariate models were used to further determine the joint association of <italic>FLT3</italic> mutation and key variables with outcomes. Because complex cytogenetic changes are used in CIBMTR cytogenetic risk determination, this variable was excluded from bivariate and multivariate modeling. Morphologic status (persistent disease <italic>vs</italic>. CR) was also included in modeling because refractory disease status at the time of allogeneic HCT has previously been shown to be an independent poor prognostic factor.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Multivariate regression models using backward selection were used to identify best-fitting models for outcomes containing <italic>FLT3</italic> mutational status and other possible confounders identified in descriptive characteristics comparison and univariate and bivariate testing.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="S7">
              <title>RESULTS</title>
              <sec id="S8">
                <title>Characteristics by FLT3 mutational status</title>
                <p id="P11">A total of 171 consecutive AML patients with available <italic>FLT3</italic> mutational testing received first-time allogeneic HCT. The median age of the study population was 55 years (range, 1−72 years). Age, gender, race, BMI, and HCT-CI distributions were similar in patient groups with <italic>vs.</italic> without <italic>FLT3</italic> mutation. The remaining patient and disease characteristics are detailed in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
                <p id="P12">The groups were also similar in morphologic status at the time of HCT (persistent disease <italic>vs.</italic> CR), time from diagnosis to HCT (&gt;180 days <italic>vs.</italic> ≤180), and number of induction (&gt;2 <italic>vs.</italic> ≤2) and combined induction and consolidation chemotherapy cycles leading to HCT (median of 3 cycles for both groups). Significantly more <italic>FLT3</italic> positive than <italic>FLT3</italic> negative patients were in cytogenetic remission at the time of HCT (94% vs. 71%, <italic>P</italic>&lt;0.01). As expected, the <italic>FLT3</italic> mutated group had higher WBC counts (≥10,000/μL) at the time of diagnosis (70% <italic>vs.</italic> 36%, <italic>P</italic>&lt;0.001), predominantly intermediate-risk CIBMTR cytogenetics with fewer instances of complex cytogenetics at diagnosis (0% <italic>vs.</italic> 21%, <italic>P</italic>&lt;0.001), and higher co-occurrence with <italic>NPM1</italic> mutation (38% <italic>vs.</italic> 11%, <italic>P</italic>&lt;0.001). <italic>FLT3</italic> mutation was less often observed in cases of preceding MDS or myeloproliferative disease (8% <italic>vs.</italic> 26%, <italic>P</italic>&lt;0.01) and therapy-related AML (0% <italic>vs.</italic> 9%, <italic>P</italic>&lt;0.05).</p>
                <p id="P13">Transplant-related characteristics were also similar between the groups, including stem cell source, donor-recipient characteristics, conditioning intensity, use of thymoglobulin or alemtuzumab, total body irradiation, number of CD34+ cells transfused, length of hospital stay, GVHD prophylaxis, and time to neutrophil engraftment (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
              </sec>
              <sec id="S9">
                <title>Engraftment and neutrophil recovery</title>
                <p id="P14">Granulocyte colony-stimulating factor was started six days after transplantation to promote neutrophil engraftment. The majority of surviving patients (&gt;99%) engrafted within 50 days of allogeneic HCT (<xref ref-type="table" rid="T2">Table 2</xref>). There was one case of graft failure among patients without <italic>FLT3</italic> mutation.</p>
              </sec>
              <sec id="S10">
                <title>Risk of relapse</title>
                <p id="P15"><xref ref-type="fig" rid="F1">Figure 1</xref> illustrates the 3-year cumulative incidence outcomes of the patient cohort following allogeneic HCT, stratified by <italic>FLT3</italic> mutational status. Patients with <italic>FLT3</italic> mutation experienced shorter median time to relapse (100 days, range: 25−495 days) compared with those without <italic>FLT3</italic> mutation (121 days, range: 26−1,142 days). The risk of relapse at 3 years was significantly higher in <italic>FLT3</italic> mutated patients (63% <italic>vs</italic>. 37%, <italic>P</italic>&lt;0.001). Among the other variables tested, high HCT-CI, high CIBMTR cytogenetic risk, and complex cytogenetics were also significantly associated with increased RR at 3 years (<xref ref-type="table" rid="T3">Table 3</xref>). We also performed bivariate analyses to explore the individual interactions of <italic>FLT3</italic> mutation with age, HCT-CI, CIBMTR cytogenetic risk, <italic>NPM1</italic> status, number of induction chemotherapy cycles, morphologic status, and conditioning intensity, and found that <italic>FLT3</italic> mutation remained a significant risk factor for relapse even after accounting for these other variables (<xref ref-type="table" rid="T4">Table 4</xref>). In the multivariate analysis, <italic>FLT3</italic> mutation (hazard ratio [HR] 3.63, 95% confidence interval [CI]: 2.13, 6.19, <italic>P</italic>&lt;0.001), high HCT-CI (HR 1.71, 95% CI: 1.04, 2.79, <italic>P</italic>&lt;0.05), high CIBMTR cytogenetic risk (HR 2.97, 95% CI: 1.52, 5.77, <italic>P</italic>=0.001), and persistent morphologic disease at transplant (HR 2.61, 95% CI: 1.44, 4.74, <italic>P</italic>&lt;0.01) variables were significantly associated with increased RR. Myeloablative conditioning (HR 0.39, 95% CI: 0.21, 0.72, <italic>P</italic>&lt;0.01) was associated with decreased RR (<xref ref-type="table" rid="T5">Table 5</xref>).</p>
              </sec>
              <sec id="S11">
                <title>GVHD (Acute and Chronic)</title>
                <p id="P16">The median time to onset of grade 2−4 acute GVHD in the study population was 36 days (range: 10−180 days) and the cumulative incidence at one year after HCT was 33%, which was similar in patients with <italic>vs.</italic> without <italic>FLT3</italic> mutation (30% <italic>vs.</italic> 34%, respectively, <italic>P</italic>=0.715). None of the other variables tested in the univariate analysis was significantly associated with 1-year acute GVHD outcomes (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
                <p id="P17">We also assessed the impact of <italic>FLT3</italic> mutational status on chronic GVHD. The median onset of chronic GVHD in the study population was 161 days (range: 52−580 days) with a cumulative incidence of 49% at one year following HCT, which was significantly lower among patients with <italic>vs.</italic> without <italic>FLT3</italic> mutation (36% <italic>vs.</italic> 54%, <italic>P</italic>&lt;0.05). WBC count ≥10,000/μL at diagnosis was also associated with decreased risk of chronic GVHD (41% <italic>vs</italic>. 54%, <italic>P</italic>&lt;0.05). In the bivariate analysis, <italic>FLT3</italic> mutation was associated with significantly lower incidence of chronic GVHD, even after adjusting for age, HCT-CI score, CIBMTR cytogenetic risk, number of induction cycles, morphologic status, and conditioning intensity (<xref ref-type="table" rid="T4">Table 4</xref>). Additionally, after incorporating all of these characteristics in the multivariate model, <italic>FLT3</italic> mutation remained the only variable significantly associated with decreased risk of chronic GVHD (HR 0.44, 95% CI: 0.25, 0.78, <italic>P</italic>&lt;0.01, <xref ref-type="table" rid="T5">Table 5</xref>).</p>
              </sec>
              <sec id="S12">
                <title>Non-relapse Mortality</title>
                <p id="P18">NRM at 3 years was significantly lower in patients with <italic>FLT3</italic> mutation (4% <italic>vs.</italic> 21%, respectively, <italic>P</italic>&lt;0.05, <xref ref-type="fig" rid="F1">Figure 1</xref>). While time from AML diagnosis to HCT (&gt;180 days <italic>vs</italic>. ≤180 days) did not impact the risk of NRM, patients who received &gt;2 induction chemotherapy cycles experienced higher NRM (32% <italic>vs.</italic> 12%, respectively, <italic>P</italic>&lt;0.05; <xref ref-type="table" rid="T3">Table 3</xref>). On bivariate testing, <italic>FLT3</italic> mutation remained significantly associated with decreased NRM after adjusting for age, HCT-CI, CIBMTR cytogenetic risk, <italic>NPM1</italic> status, number of induction cycles, morphologic status, and conditioning intensity (<xref ref-type="table" rid="T4">Table 4</xref>). This finding was also seen in the multivariate analysis (HR 0.21, 95% CI: 0.05, 0.92, <italic>P</italic>&lt;0.05).</p>
              </sec>
              <sec id="S13">
                <title>Disease-free Survival</title>
                <p id="P19"><italic>FLT3</italic> mutational status was associated with a trend toward inferior DFS at 3 years (<italic>FLT3</italic> mutation: 32% <italic>vs.</italic> no <italic>FLT3</italic> mutation: 41%, <italic>P</italic>=0.065, <xref ref-type="fig" rid="F1">Figure 1</xref>). CIBMTR cytogenetic risk (high: 13% <italic>vs.</italic> intermediate: 45% <italic>vs</italic>. low: 100%, <italic>P</italic>=0.001), complex cytogenetics (≥3 abnormalities at diagnosis: 11% <italic>vs</italic>. &lt;3 abnormalities: 44%, <italic>P</italic>&lt;0.001), and number of induction cycles (&gt;2 inductions: 15% <italic>vs.</italic> ≤2 inductions: 46%, <italic>P</italic>&lt;0.01) variables at diagnosis were associated with significantly decreased DFS (<xref ref-type="table" rid="T3">Table 3</xref>). In the bivariate models, <italic>FLT3</italic> mutation was shown to negatively impact DFS when adjusting for CIBMTR cytogenetic risk and <italic>NPM1</italic> status variables only (<xref ref-type="table" rid="T4">Table 4</xref>). However, in the multivariate model that accounted for the interaction of multiple potential confounders, <italic>FLT3</italic> mutation (HR 2.05, 95% CI: 1.29, 3.27, <italic>P</italic>&lt;0.01), high CIBMTR cytogenetic risk (HR 2.35, 95% CI: 1.34, 4.10, <italic>P</italic>&lt;0.01), &gt;2 two induction cycles (HR 1.73, 95% CI: 1.07, 2.78, <italic>P</italic>&lt;0.05), and persistent morphologic disease at time of transplant (HR 2.52, 95% CI: 1.51, 4.21, <italic>P</italic>&lt;0.001) were all found to be significantly associated with inferior DFS (<xref ref-type="table" rid="T5">Table 5</xref>).</p>
              </sec>
              <sec id="S14">
                <title>Overall survival</title>
                <p id="P20">The 3-year overall survival was decreased among patients with <italic>vs.</italic> without <italic>FLT3</italic> mutation, but the difference was not statistically significant (38% <italic>vs.</italic> 48%, <italic>P</italic>=0.334, <xref ref-type="fig" rid="F1">Figure 1</xref>) with a median survival of 244 days (range: 57 to 2,001 days) and 368 days (range: 46 to 2,405 days), respectively. Among the other variables tested, high CIBMTR cytogenetic risk, presence of complex cytogenetics at diagnosis, and &gt;2 induction chemotherapy cycles were each associated with significantly lower 3-year overall survival (<xref ref-type="table" rid="T3">Table 3</xref>). In the bivariate models, <italic>FLT3</italic> mutation negatively impacted overall survival (HR 1.69, 95% CI: 1.04, 2.75, <italic>P</italic>&lt;0.05) after adjusting for CIBMTR cytogenetic risk at diagnosis only (<xref ref-type="table" rid="T4">Table 4</xref>). However, when accounting for all potential confounders in the multivariate model, <italic>FLT3</italic> mutation (HR 1.92, 95% CI 1.14, 3.24, <italic>P</italic>&lt;0.05), high CIBMTR cytogenetic risk (HR 1.93, 95% CI 1.08, 3.48, <italic>P</italic>&lt;0.05), &gt;2 induction cycles (HR 1.87, 95% CI: 1.14, 3.09, <italic>P</italic>&lt;0.05), and persistent morphologic disease at transplant (HR 2.15, 95% CI 1.23, 3.78, <italic>P</italic>&lt;0.01) variables significantly decreased overall survival (<xref ref-type="table" rid="T5">Table 5</xref>). All causes of mortality are detailed in <xref ref-type="supplementary-material" rid="SD1">Supplemental Table S5</xref>.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="S15">
              <title>DISCUSSION</title>
              <p id="P21">In this study, we examined the frequency of <italic>FLT3</italic> mutation in children and adults with AML who underwent allogeneic HCT at our center over a 7-year study period. Patients diagnosed before 2007 were not genetically defined at diagnosis for this mutation. Given conflicting reports,<sup><xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R31" ref-type="bibr">31</xref></sup> we sought to further clarify the impact of <italic>FLT3</italic> mutational status on HCT outcomes in a large, single institution cohort transplanted between 2008 and 2014. Consistent with the literature, <italic>FLT3</italic> mutated patients comprised approximately 29% of our study population.<sup><xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R4" ref-type="bibr">4</xref></sup> We found that <italic>FLT3</italic> mutation was an independent factor for increased RR that translated into inferior DFS and overall survival after adjusting for potential confounding covariates. The low NRM was likely due to a higher RR, which is a competing risk for NRM. The present findings extend the observations from previous studies that have reported the outcomes of <italic>FLT3</italic> mutational AML after allogeneic HCT (<xref ref-type="supplementary-material" rid="SD1">Supplemental Table S1</xref>) and substantiate the need for optimizing risk stratification of AML patients at the time of transplant.</p>
              <p id="P22">Cytogenetic characterization at diagnosis is recognized as the most powerful independent prognostic factor in AML. In recent years, risk-stratification has been refined by molecular markers, such as the <italic>FLT3</italic> gene. Herein, our data support the importance of carefully characterizing disease-specific variables in AML patients presenting for allogeneic transplantation. Our analyses demonstrate that, in addition to <italic>FLT3</italic> mutation, high-risk CIBMTR cytogenetics at diagnosis and persistent morphologic disease at transplant conferred an increased RR and lowered DFS and overall survival.</p>
              <p id="P23">Recently, the number of induction courses required to achieve morphologic remission in AML was shown to provide independent prognostic information for outcome after transplant.<sup><xref rid="R38" ref-type="bibr">38</xref></sup> We therefore included this variable in our analyses and similarly demonstrated that patients who received greater than two induction cycles experienced decreased DFS and overall survival. These data provide insight into disease-specific factors that independently contribute to relapse and highlight the need to identify allogeneic HCT candidates for risk-stratified treatment recommendations. For example, patients who are destined to relapse early after allogeneic HCT (<italic>FLT3</italic> mutation, high CIBMTR risk cytogenetics, and/or persistent morphologic disease) may benefit from post-transplant interventions or other non-transplant clinical trial options. Unfortunately, there remains a paucity of prospective, multi-center studies that have rigorously evaluated such strategies, such as donor leukocyte infusions,<sup><xref rid="R39" ref-type="bibr">39</xref></sup> targeted therapies,<sup><xref rid="R40" ref-type="bibr">40</xref></sup> hypomethylating agents,<sup><xref rid="R41" ref-type="bibr">41</xref></sup> or other immune checkpoint blockade therapy.<sup><xref rid="R42" ref-type="bibr">42</xref></sup> The optimal timing, dosing, duration, and type of strategy in the post-transplant setting are unknown and need to be explored.</p>
              <p id="P24">Interestingly, <italic>FLT3</italic> mutated patients with intermediate CIBMTR cytogenetic risk experienced increased RR similar to those with high CIBMTR cytogenetic risk (data not shown). However, DFS and overall survival were not as comparably reduced as seen in the high CIBMTR cytogenetic risk group. These data again highlight the potential role for implementing pre-emptive FLT3-targeted therapies to reduce the relapse hazard in these molecularly defined patients.</p>
              <p id="P25">Similar to recent studies examining the influence of age on allogeneic HCT outcomes,<sup><xref rid="R50" ref-type="bibr">50</xref></sup> our study did not indicate that patients &gt;60 years of age experienced increased relapse or decreased survival. It is possible that our data represent selection of older individuals with greater fitness who met institutional criteria for allogeneic HCT or treatment according to a clinical trial. Nonetheless, we further explored other patient-specific comorbid conditions as measured by the HCT-CI<sup><xref rid="R33" ref-type="bibr">33</xref></sup> to help estimate outcomes following transplant and found that high HCT-CI was associated with increased RR. Although not statistically significant, this resulted in a trend toward inferior DFS and overall survival. Allogeneic HCT is increasingly offered to older patients, and identifying suitable patients could improve the effectiveness of transplantation. In our study, myeloablative conditioning was associated with lower RR and increased DFS and overall survival, suggesting a potentially protective effect in this population. It is possible that a subset of chronologically older age individuals would benefit from and tolerate increased intensity regimens. Nonetheless, we recognize that further work is needed to confirm our observations.</p>
              <p id="P26">We recognize the limitation of our single-center, retrospective cohort study. Nonetheless, allogeneic HCT is increasingly a preferred treatment option for <italic>FLT3</italic> mutational AML patients, particularly with increased availability of donors and use of reduced intensity conditioning regimens, and such studies provide direction for well-designed prospective clinical trials. There is ongoing need to develop novel, preemptive post-transplant strategies in the setting of clinical research, particularly for high-risk AML, to help address malignant relapse.<sup><xref rid="R52" ref-type="bibr">52</xref></sup> Our study supports the recognition of <italic>FLT3</italic> mutation as an independent marker for high-risk disease and highlights the importance of carefully examining disease, patient, and transplant-specific variables, collectively, to identify suitable allogeneic HCT candidates and inform post-transplant expectations. Furthermore, minimal residual disease monitoring has been increasingly recognized as a source of additional valuable prognostic information that complements molecular and cytogenetic risk,<sup><xref rid="R53" ref-type="bibr">53</xref></sup> and combined utilization of these factors may prove crucial to optimal prognostication.</p>
              <p id="P27">Strengths of our study include transplant practices in the current era (2008 to 2014) with detailed patient, disease, and transplant-specific variables. To our knowledge, based on the literature review (detailed in <xref ref-type="supplementary-material" rid="SD1">Supplemental Table S1</xref>), the present analysis represents one of the largest study populations with known <italic>FLT3</italic> mutational status that have undergone allogeneic HCT with the best available donor (related or unrelated) after either myeloablative or reduced intensity conditioning. At the same time, we recognize that the heterogeneity of this patient population is also a limitation, precluding us from forming generalized conclusions, such as in pediatric patients. We performed a sub-group analysis of children &lt;18 years of age, and although the sample size was small, we observed similar trends in outcomes between the overall study population and pediatric patients (data not shown). We attempted to control for potential confounding covariates by performing both bivariate and multivariate analyses. Clearly, future studies are needed with larger populations from multi-center collaborations to confirm the observations herein.</p>
              <p id="P28">In summary, the key finding of this study is the adverse outcomes associated with <italic>FLT3</italic> mutant AML. The data herein highlight the early kinetics of malignant relapse occurring within the first 100 days of transplanted patients. Therefore, it is desirable to develop novel post-transplant strategies that could effectively impact early relapse hazards.</p>
            </sec>
            <sec sec-type="supplementary-material" id="SM">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="SD1">
                <label>1</label>
                <media xlink:href="NIHMS699693-supplement-1.docx" orientation="portrait" xlink:type="simple" id="d37e1149" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD2">
                <label>2</label>
                <media xlink:href="NIHMS699693-supplement-2.pdf" orientation="portrait" xlink:type="simple" id="d37e1153" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S16">
              <title>ACKNOWLEDGEMENTS</title>
              <p>We are grateful to the patients, their families, and the clinical personnel who participated in this study. We thank Tracey Churay and Ashley Crouch and the BMT Program Team at the University of Michigan Clinical Trials Office for data collection and management. SWC is an A. Alfred Taubman Institute/Edith Briskin/SKS Foundation Emerging Scholar. SWC is supported by a grant from the National Institutes of Health (1K23AI091623).</p>
            </ack>
            <fn-group>
              <fn id="FN1">
                <p id="P29">FINANCIAL DISCLOSURE STATEMENT</p>
                <p id="P30">Conflicts of interest: none</p>
              </fn>
              <fn id="FN2">
                <p id="P31">AUTHORSHIP</p>
                <p id="P32">Y.S. collected and analyzed data, and drafted and approved the manuscript; Y.L. analyzed data and approved the manuscript; L.C., D.A.H., K.A.C, and E.G. collected data and approved the manuscript; D.C., S.G., A.P., P.R., M.R., J.C., A.H., C.K., J.L., and G.Y. cared for patients and approved the manuscript; T.B. designed the study, analyzed data, and approved the manuscript; J.M., B.P., and D.B. designed the study, cared for patients, and approved the manuscript. S.W.C. designed the study, cared for patients, collected and analyzed data, and drafted and approved the manuscript.</p>
              </fn>
              <fn id="FN3">
                <p id="P33">Supplementary information is available at the journal's website.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="R1">
                <label>1</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schlenk</surname>
                      <given-names>RF</given-names>
                    </name>
                    <name>
                      <surname>Pasquini</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Perez</surname>
                      <given-names>WS</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Krauter</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Antin</surname>
                      <given-names>JH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2008</year>
                  <volume>14</volume>
                  <issue>2</issue>
                  <fpage>187</fpage>
                  <lpage>196</lpage>
                  <comment>doi: 10.1016/j.bbmt.2007.10.006</comment>
                </element-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schnittger</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Schoch</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Dugas</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kern</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Staib</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Wuchter</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.</article-title>
                  <source>Blood</source>
                  <year>2002</year>
                  <volume>100</volume>
                  <issue>1</issue>
                  <fpage>59</fpage>
                  <lpage>66</lpage>
                  <pub-id pub-id-type="pmid">12070009</pub-id>
                </element-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frohling</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Schlenk</surname>
                      <given-names>RF</given-names>
                    </name>
                    <name>
                      <surname>Breitruck</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Benner</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kreitmeier</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tobis</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.</article-title>
                  <source>Blood</source>
                  <year>2002</year>
                  <volume>100</volume>
                  <issue>13</issue>
                  <fpage>4372</fpage>
                  <lpage>4380</lpage>
                  <comment>doi: 10.1182/blood-2002-05-1440</comment>
                  <pub-id pub-id-type="pmid">12393388</pub-id>
                </element-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kottaridis</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Gale</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Frew</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Harrison</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Langabeer</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Belton</surname>
                      <given-names>AA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.</article-title>
                  <source>Blood</source>
                  <year>2001</year>
                  <volume>98</volume>
                  <issue>6</issue>
                  <fpage>1752</fpage>
                  <lpage>1759</lpage>
                  <pub-id pub-id-type="pmid">11535508</pub-id>
                </element-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yamamoto</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Kiyoi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Nakano</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Suzuki</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kodera</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Miyawaki</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.</article-title>
                  <source>Blood</source>
                  <year>2001</year>
                  <volume>97</volume>
                  <issue>8</issue>
                  <fpage>2434</fpage>
                  <lpage>2439</lpage>
                  <pub-id pub-id-type="pmid">11290608</pub-id>
                </element-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Whitman</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Archer</surname>
                      <given-names>KJ</given-names>
                    </name>
                    <name>
                      <surname>Feng</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Baldus</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Becknell</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Carlson</surname>
                      <given-names>BD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.</article-title>
                  <source>Cancer research</source>
                  <year>2001</year>
                  <volume>61</volume>
                  <issue>19</issue>
                  <fpage>7233</fpage>
                  <lpage>7239</lpage>
                  <pub-id pub-id-type="pmid">11585760</pub-id>
                </element-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pasquini</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Z</given-names>
                    </name>
                  </person-group>
                  <source>Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides</source>
                  <year>2013</year>
                </element-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vyas</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Appelbaum</surname>
                      <given-names>FR</given-names>
                    </name>
                    <name>
                      <surname>Craddock</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Allogeneic hematopoietic cell transplantation for acute myeloid leukemia.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2015</year>
                  <volume>21</volume>
                  <issue>1</issue>
                  <fpage>8</fpage>
                  <lpage>15</lpage>
                  <comment>doi: 10.1016/j.bbmt.2014.10.026</comment>
                </element-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gale</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Hills</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kottaridis</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Srirangan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Wheatley</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Burnett</surname>
                      <given-names>AK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.</article-title>
                  <source>Blood</source>
                  <year>2005</year>
                  <volume>106</volume>
                  <issue>10</issue>
                  <fpage>3658</fpage>
                  <lpage>3665</lpage>
                  <comment>doi: 10.1182/blood-2005-03-1323</comment>
                  <pub-id pub-id-type="pmid">16076872</pub-id>
                </element-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bornhauser</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Illmer</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Schaich</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Soucek</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ehninger</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Thiede</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.</article-title>
                  <source>Blood</source>
                  <year>2007</year>
                  <volume>109</volume>
                  <issue>5</issue>
                  <fpage>2264</fpage>
                  <lpage>2265</lpage>
                  <comment>author reply 2265. doi: 10.1182/blood-2006-09-047225</comment>
                  <pub-id pub-id-type="pmid">17312001</pub-id>
                </element-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Doubek</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Muzik</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Szotkowski</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Koza</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Cetkovsky</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kozak</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT).</article-title>
                  <source>Neoplasma</source>
                  <year>2007</year>
                  <volume>54</volume>
                  <issue>1</issue>
                  <fpage>89</fpage>
                  <lpage>94</lpage>
                  <pub-id pub-id-type="pmid">17233551</pub-id>
                </element-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schlenk</surname>
                      <given-names>RF</given-names>
                    </name>
                    <name>
                      <surname>Dohner</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Krauter</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Frohling</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Corbacioglu</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bullinger</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.</article-title>
                  <source>The New England journal of medicine</source>
                  <year>2008</year>
                  <volume>358</volume>
                  <issue>18</issue>
                  <fpage>1909</fpage>
                  <lpage>1918</lpage>
                  <comment>doi: 101056/NEJMoa074306</comment>
                  <pub-id pub-id-type="pmid">18450602</pub-id>
                </element-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kim</surname>
                      <given-names>YK</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>HN</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Ahn</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia.</article-title>
                  <source>The Korean journal of hematology</source>
                  <year>2010</year>
                  <volume>45</volume>
                  <issue>1</issue>
                  <fpage>36</fpage>
                  <lpage>45</lpage>
                  <comment>doi: 10.5045/kjh.2010.45.1.36</comment>
                  <pub-id pub-id-type="pmid">21120161</pub-id>
                </element-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>DeZern</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Sung</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>BD</given-names>
                    </name>
                    <name>
                      <surname>Karp</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Gore</surname>
                      <given-names>SD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2011</year>
                  <volume>17</volume>
                  <issue>9</issue>
                  <fpage>1404</fpage>
                  <lpage>1409</lpage>
                  <comment>doi: 101016/j.bbmt.2011.02.003</comment>
                </element-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ehninger</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Bornhauser</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kramer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rollig</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wandt</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Hanel</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial.</article-title>
                  <source>ASH Annual Meeting Abstracts</source>
                  <year>2011</year>
                  <volume>118</volume>
                  <issue>21</issue>
                  <fpage>497</fpage>
                </element-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kayser</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Zucknick</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dohner</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Krauter</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kohne</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>Horst</surname>
                      <given-names>HA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.</article-title>
                  <source>Blood</source>
                  <year>2012</year>
                  <volume>119</volume>
                  <issue>2</issue>
                  <fpage>551</fpage>
                  <lpage>558</lpage>
                  <comment>doi: 101182/blood-2011-07-367508</comment>
                  <pub-id pub-id-type="pmid">22096250</pub-id>
                </element-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brunet</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Labopin</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Esteve</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Cornelissen</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Socie</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Iori</surname>
                      <given-names>AP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.</article-title>
                  <source>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <issue>7</issue>
                  <fpage>735</fpage>
                  <lpage>741</lpage>
                  <comment>doi: 101200/JCO.2011.36.9868</comment>
                  <pub-id pub-id-type="pmid">22291086</pub-id>
                </element-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sengsayadeth</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Jagasia</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Engelhardt</surname>
                      <given-names>BG</given-names>
                    </name>
                    <name>
                      <surname>Kassim</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Strickland</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Goodman</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.</article-title>
                  <source>Bone Marrow Transplant</source>
                  <year>2012</year>
                  <volume>47</volume>
                  <issue>12</issue>
                  <fpage>1535</fpage>
                  <lpage>1537</lpage>
                  <comment>doi: 10.1038/bmt.2012.88</comment>
                  <pub-id pub-id-type="pmid">22659680</pub-id>
                </element-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Laboure</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Dulucq</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Labopin</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tabrizi</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Guerin</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Pigneux</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <issue>12</issue>
                  <fpage>1845</fpage>
                  <lpage>1850</lpage>
                  <comment>doi: 101016/j.bbmt.2012.06.012</comment>
                </element-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Guieze</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Cornillet-Lefebvre</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Lioure</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Blanchet</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Pigneux</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Recher</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.</article-title>
                  <source>American journal of hematology</source>
                  <year>2012</year>
                  <volume>87</volume>
                  <issue>12</issue>
                  <fpage>1052</fpage>
                  <lpage>1056</lpage>
                  <comment>doi: 101002/ajh.23311</comment>
                  <pub-id pub-id-type="pmid">22911473</pub-id>
                </element-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pfeiffer</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Schleuning</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mayer</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Haude</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Tischer</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Buchholz</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.</article-title>
                  <source>Haematologica</source>
                  <year>2013</year>
                  <volume>98</volume>
                  <issue>4</issue>
                  <fpage>518</fpage>
                  <lpage>525</lpage>
                  <comment>doi: 10.3324/haematol.2012.070235</comment>
                  <pub-id pub-id-type="pmid">22983588</pub-id>
                </element-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lin</surname>
                      <given-names>PH</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>HI</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>LY</given-names>
                    </name>
                    <name>
                      <surname>Bai</surname>
                      <given-names>LY</given-names>
                    </name>
                    <name>
                      <surname>Chiu</surname>
                      <given-names>CF</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3.</article-title>
                  <source>Leukemia research</source>
                  <year>2013</year>
                  <volume>37</volume>
                  <issue>3</issue>
                  <fpage>287</fpage>
                  <lpage>292</lpage>
                  <comment>doi: 10.1016/j.leukres.2012.10.005</comment>
                  <pub-id pub-id-type="pmid">23276395</pub-id>
                </element-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pratcorona</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Brunet</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Nomdedeu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ribera</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Tormo</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Duarte</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Favorable outcome of patients with acute myeloid leukemia harboring a low allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.</article-title>
                  <source>Blood</source>
                  <year>2013</year>
                  <volume>121</volume>
                  <issue>14</issue>
                  <fpage>2734</fpage>
                  <lpage>2738</lpage>
                  <comment>doi: 10.1182/blood-2012-06-431122</comment>
                  <pub-id pub-id-type="pmid">23377436</pub-id>
                </element-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Burke</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Wagner</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Cao</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Ustun</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Verneris</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2013</year>
                  <volume>19</volume>
                  <issue>7</issue>
                  <fpage>1021</fpage>
                  <lpage>1025</lpage>
                  <comment>doi: 10.1016/j.bbmt.2013.04.001</comment>
                </element-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>YC</given-names>
                    </name>
                    <name>
                      <surname>Hsiao</surname>
                      <given-names>HH</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>WC</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>TC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation.</article-title>
                  <source>Genetics and molecular research : GMR</source>
                  <year>2013</year>
                  <volume>12</volume>
                  <issue>4</issue>
                  <fpage>5414</fpage>
                  <lpage>5423</lpage>
                  <comment>doi: 104238/2013.November.11.3</comment>
                  <pub-id pub-id-type="pmid">24301914</pub-id>
                </element-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yang</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Tian</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Qiu</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>[Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation].</article-title>
                  <source>Zhonghua nei ke za zhi</source>
                  <year>2014</year>
                  <volume>53</volume>
                  <issue>2</issue>
                  <fpage>94</fpage>
                  <lpage>98</lpage>
                  <pub-id pub-id-type="pmid">24767158</pub-id>
                </element-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chou</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Tang</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Hou</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Chou</surname>
                      <given-names>WC</given-names>
                    </name>
                    <name>
                      <surname>Hu</surname>
                      <given-names>FC</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>CY</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations.</article-title>
                  <source>Leukemia research</source>
                  <year>2014</year>
                  <volume>38</volume>
                  <issue>11</issue>
                  <fpage>1278</fpage>
                  <lpage>1284</lpage>
                  <comment>doi: 101016/j.leukres.2014.08.012</comment>
                  <pub-id pub-id-type="pmid">25260824</pub-id>
                </element-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Locatelli</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Masetti</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Rondelli</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Zecca</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Fagioli</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Rovelli</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study.</article-title>
                  <source>Bone Marrow Transplant</source>
                  <year>2014</year>
                  <comment>doi: 10.1038/bmt.2014.246</comment>
                </element-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schlenk</surname>
                      <given-names>RF</given-names>
                    </name>
                    <name>
                      <surname>Kayser</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Bullinger</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Kobbe</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Casper</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ringhoffer</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.</article-title>
                  <source>Blood</source>
                  <year>2014</year>
                  <volume>124</volume>
                  <issue>23</issue>
                  <fpage>3441</fpage>
                  <lpage>3449</lpage>
                  <comment>doi: 101182/blood-2014-05-578070</comment>
                  <pub-id pub-id-type="pmid">25270908</pub-id>
                </element-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schetelig</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Schaich</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schafer-Eckart</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Hanel</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Aulitzky</surname>
                      <given-names>WE</given-names>
                    </name>
                    <name>
                      <surname>Einsele</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hematopoietic cell transplantation in patients with intermediate and high-risk AML - results from the randomized study alliance leukemia (SAL) AML 2003 trial.</article-title>
                  <source>Leukemia</source>
                  <year>2014</year>
                  <comment>doi: 10.1038/leu.2014.335</comment>
                </element-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schechter</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Gassas</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Pollard</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Meshinchi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Zaidman</surname>
                      <given-names>I</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication-Positive Acute Myelogenous Leukemia.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2015</year>
                  <volume>21</volume>
                  <issue>1</issue>
                  <fpage>172</fpage>
                  <lpage>175</lpage>
                  <comment>doi: 10.1016/j.bbmt.2014.08.008</comment>
                </element-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hanauer</surname>
                      <given-names>DA</given-names>
                    </name>
                  </person-group>
                  <article-title>EMERSE: The Electronic Medical Record Search Engine. AMIA ... Annual Symposium proceedings / AMIA Symposium.</article-title>
                  <source>AMIA Symposium</source>
                  <year>2006</year>
                  <fpage>941</fpage>
                  <pub-id pub-id-type="pmid">17238560</pub-id>
                </element-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sorror</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Maris</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Storb</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Baron</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Sandmaier</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Maloney</surname>
                      <given-names>DG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.</article-title>
                  <source>Blood</source>
                  <year>2005</year>
                  <volume>106</volume>
                  <issue>8</issue>
                  <fpage>2912</fpage>
                  <lpage>2919</lpage>
                  <comment>doi: 101182/blood-2005-05-2004</comment>
                  <pub-id pub-id-type="pmid">15994282</pub-id>
                </element-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Slovak</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Kopecky</surname>
                      <given-names>KJ</given-names>
                    </name>
                    <name>
                      <surname>Cassileth</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Harrington</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Theil</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Mohamed</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.</article-title>
                  <source>Blood</source>
                  <year>2000</year>
                  <volume>96</volume>
                  <issue>13</issue>
                  <fpage>4075</fpage>
                  <lpage>4083</lpage>
                  <pub-id pub-id-type="pmid">11110676</pub-id>
                </element-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fine</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Gray</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>A proportional hazards model for the subdistribution of a competing risk.</article-title>
                  <source>J Am Stat Assoc</source>
                  <year>1999</year>
                  <volume>94</volume>
                  <fpage>496</fpage>
                  <lpage>509</lpage>
                </element-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gray</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>A class of K-sample tests for comparing the cumulative incidence of a competing risk.</article-title>
                  <source>Ann Stat</source>
                  <year>1988</year>
                  <volume>16</volume>
                  <fpage>1141</fpage>
                  <lpage>1154</lpage>
                </element-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kaplan</surname>
                      <given-names>EL</given-names>
                    </name>
                    <name>
                      <surname>Meier</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Nonparametric-estimation from incomplete observations.</article-title>
                  <source>J Am Stat Assoc</source>
                  <year>1958</year>
                  <volume>53</volume>
                  <fpage>457</fpage>
                  <lpage>481</lpage>
                </element-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Walter</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Sandmaier</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Storer</surname>
                      <given-names>BE</given-names>
                    </name>
                    <name>
                      <surname>Godwin</surname>
                      <given-names>CD</given-names>
                    </name>
                    <name>
                      <surname>Buckley</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Pagel</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2015</year>
                  <volume>21</volume>
                  <issue>2</issue>
                  <fpage>373</fpage>
                  <lpage>378</lpage>
                  <comment>doi: 101016/j.bbmt.2014.09.022</comment>
                </element-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schroeder</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Rachlis</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bug</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Stelljes</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Klein</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Steckel</surname>
                      <given-names>NK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2014</year>
                  <comment>e-pub ahead of print 2014/12/30; doi: S1083-8791(14)01416-5 [pii]</comment>
                </element-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>YB</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Lane</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Connolly</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Del Rio</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Valles</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2014</year>
                  <volume>20</volume>
                  <issue>12</issue>
                  <fpage>2042</fpage>
                  <lpage>2048</lpage>
                  <comment>doi: 101016/j.bbmt.2014.09.007</comment>
                </element-citation>
              </ref>
              <ref id="R41">
                <label>41</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Platzbecker</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Wermke</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Radke</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Oelschlaegel</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Seltmann</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Kiani</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.</article-title>
                  <source>Leukemia</source>
                  <year>2012</year>
                  <volume>26</volume>
                  <issue>3</issue>
                  <fpage>381</fpage>
                  <lpage>389</lpage>
                  <comment>e pub ahead of print 2011/09/03; doi: 10.1038/leu.2011.234</comment>
                  <pub-id pub-id-type="pmid">21886171</pub-id>
                </element-citation>
              </ref>
              <ref id="R42">
                <label>42</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brahmer</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Tykodi</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Chow</surname>
                      <given-names>LQ</given-names>
                    </name>
                    <name>
                      <surname>Hwu</surname>
                      <given-names>WJ</given-names>
                    </name>
                    <name>
                      <surname>Topalian</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Hwu</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.</article-title>
                  <source>The New England journal of medicine</source>
                  <year>2012</year>
                  <volume>366</volume>
                  <issue>26</issue>
                  <fpage>2455</fpage>
                  <lpage>2465</lpage>
                  <comment>e-pub ahead of print 2012/06/05; doi: 10.1056/NEJMoa1200694</comment>
                  <pub-id pub-id-type="pmid">22658128</pub-id>
                </element-citation>
              </ref>
              <ref id="R43">
                <label>43</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Antar</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kharfan-Dabaja</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Mahfouz</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bazarbachi</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.</article-title>
                  <source>Clinical lymphoma, myeloma &amp; leukemia</source>
                  <year>2014</year>
                  <comment>doi: 10.1016/j.clml.2014.12.005</comment>
                </element-citation>
              </ref>
              <ref id="R44">
                <label>44</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sharma</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ravandi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Bayraktar</surname>
                      <given-names>UD</given-names>
                    </name>
                    <name>
                      <surname>Chiattone</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bashir</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Giralt</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2011</year>
                  <volume>17</volume>
                  <issue>12</issue>
                  <fpage>1874</fpage>
                  <lpage>1877</lpage>
                  <comment>doi: 10.1016/j.bbmt.2011.07.011</comment>
                </element-citation>
              </ref>
              <ref id="R45">
                <label>45</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Metzelder</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Schroeder</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Finck</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Scholl</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Fey</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gotze</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.</article-title>
                  <source>Leukemia</source>
                  <year>2012</year>
                  <volume>26</volume>
                  <issue>11</issue>
                  <fpage>2353</fpage>
                  <lpage>2359</lpage>
                  <comment>doi: 10.1038/leu.2012.105</comment>
                  <pub-id pub-id-type="pmid">22504140</pub-id>
                </element-citation>
              </ref>
              <ref id="R46">
                <label>46</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Takahashi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kantarjian</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Pemmaraju</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Andreeff</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Borthakur</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Faderl</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.</article-title>
                  <source>British journal of haematology</source>
                  <year>2013</year>
                  <volume>161</volume>
                  <issue>5</issue>
                  <fpage>659</fpage>
                  <lpage>666</lpage>
                  <comment>doi: 10.1111/bjh.12299</comment>
                  <pub-id pub-id-type="pmid">23530930</pub-id>
                </element-citation>
              </ref>
              <ref id="R47">
                <label>47</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Song</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Valdez</surname>
                      <given-names>BC</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Champlin</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Andersson</surname>
                      <given-names>BS</given-names>
                    </name>
                  </person-group>
                  <article-title>Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2014</year>
                  <volume>20</volume>
                  <issue>11</issue>
                  <fpage>1687</fpage>
                  <lpage>1695</lpage>
                  <comment>doi: 101016/j.bbmt.2014.08.003</comment>
                </element-citation>
              </ref>
              <ref id="R48">
                <label>48</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wander</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Levis</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Fathi</surname>
                      <given-names>AT</given-names>
                    </name>
                  </person-group>
                  <article-title>The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.</article-title>
                  <source>Therapeutic advances in hematology</source>
                  <year>2014</year>
                  <volume>5</volume>
                  <issue>3</issue>
                  <fpage>65</fpage>
                  <lpage>77</lpage>
                  <comment>doi: 10.1177/2040620714532123</comment>
                  <pub-id pub-id-type="pmid">24883179</pub-id>
                </element-citation>
              </ref>
              <ref id="R49">
                <label>49</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zimmerman</surname>
                      <given-names>EI</given-names>
                    </name>
                    <name>
                      <surname>Turner</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Buaboonnam</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Orwick</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Roberts</surname>
                      <given-names>MS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.</article-title>
                  <source>Blood</source>
                  <year>2013</year>
                  <volume>122</volume>
                  <issue>22</issue>
                  <fpage>3607</fpage>
                  <lpage>3615</lpage>
                  <comment>doi: 10.1182/blood-2013-07-513044</comment>
                  <pub-id pub-id-type="pmid">24046014</pub-id>
                </element-citation>
              </ref>
              <ref id="R50">
                <label>50</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Federmann</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Faul</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Meisner</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Vogel</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Kanz</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Bethge</surname>
                      <given-names>WA</given-names>
                    </name>
                  </person-group>
                  <article-title>Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged 60.</article-title>
                  <source>Bone Marrow Transplant</source>
                  <year>2015</year>
                  <comment>doi: 101038/bmt.2014.292</comment>
                </element-citation>
              </ref>
              <ref id="R51">
                <label>51</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sorror</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Storb</surname>
                      <given-names>RF</given-names>
                    </name>
                    <name>
                      <surname>Sandmaier</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Maziarz</surname>
                      <given-names>RT</given-names>
                    </name>
                    <name>
                      <surname>Pulsipher</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Maris</surname>
                      <given-names>MB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.</article-title>
                  <source>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</source>
                  <year>2014</year>
                  <volume>32</volume>
                  <issue>29</issue>
                  <fpage>3249</fpage>
                  <lpage>3256</lpage>
                  <comment>doi: 101200/JCO.2013.53.8157</comment>
                  <pub-id pub-id-type="pmid">25154831</pub-id>
                </element-citation>
              </ref>
              <ref id="R52">
                <label>52</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pavletic</surname>
                      <given-names>SZ</given-names>
                    </name>
                    <name>
                      <surname>Kumar</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mohty</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>de Lima</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Foran</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Pasquini</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.</article-title>
                  <source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</source>
                  <year>2010</year>
                  <volume>16</volume>
                  <issue>7</issue>
                  <fpage>871</fpage>
                  <lpage>890</lpage>
                  <comment>doi: 10.1016/j.bbmt.2010.04.004</comment>
                </element-citation>
              </ref>
              <ref id="R53">
                <label>53</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Walter</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Gooley</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Wood</surname>
                      <given-names>BL</given-names>
                    </name>
                    <name>
                      <surname>Milano</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Fang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sorror</surname>
                      <given-names>ML</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.</article-title>
                  <source>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>9</issue>
                  <fpage>1190</fpage>
                  <lpage>1197</lpage>
                  <comment>e-pub ahead of print 2011/02/02; doi: 10.1200/JCO.2010.31.8121</comment>
                  <pub-id pub-id-type="pmid">21282535</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig id="F1" orientation="portrait" position="float">
              <label>Figure 1</label>
              <caption>
                <p>Three-year Cumulative Incidence Outcomes by <italic>FLT3</italic> Mutational Status. A) Relapse Risk, B) Non-relapse Mortality, C) Disease-free Survival, D) Overall Survival Solid line: <italic>FLT3</italic> mutation positive; Dashed line: <italic>FLT3</italic> mutation negative</p>
              </caption>
              <graphic xlink:href="nihms-699693-f0001"/>
            </fig>
            <table-wrap id="T1" position="float" orientation="portrait">
              <label>Table 1</label>
              <caption>
                <p>Patient and Disease Characteristics by <italic>FLT3</italic> Mutational Status</p>
              </caption>
              <table frame="void" rules="none">
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th align="center" valign="top" rowspan="1" colspan="1"><italic>FLT3</italic> Recorded</th>
                    <th align="center" valign="top" rowspan="1" colspan="1"><italic>FLT3</italic> Negative</th>
                    <th align="center" valign="top" rowspan="1" colspan="1"><italic>FLT3</italic> Positive</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                  </tr>
                  <tr>
                    <th colspan="5" align="center" valign="top" rowspan="1">
                      <hr/>
                    </th>
                  </tr>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">N (%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">N (%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">N (%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Patients (count)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">171</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">121</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">50</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Age (years)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Median [Range]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">55 [1 - 72]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">55 [1 - 72]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54 [3 - 71]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.519</td>
                  </tr>
                  <tr>
                    <td colspan="5" align="center" valign="top" rowspan="1">
                      <hr/>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;60 years</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">117 (68)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">81 (67)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">36 (72)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.518</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">≥60 years</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54 (32)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">40 (33)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14 (28)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Gender</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Female</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">75 (44)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">51 (42)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">24 (48)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.483</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Male</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">96 (56)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">70 (58)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">26 (52)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Race/Ethnicity</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">White (Non-Hispanic)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">152 (89)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">109 (90)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">43 (86)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.070</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">White (Hispanic)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6 (4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4 (3)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2 (4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Black</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6 (4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6 (5)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Asian</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2 (4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Other</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3 (6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>BMI</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;18.5 kg/m<sup>2</sup></td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5 (3)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4 (3)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.900</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">18.5-24.9 kg/m<sup>2</sup></td>
                    <td align="center" valign="top" rowspan="1" colspan="1">39 (23)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">26 (21)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13 (26)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">25.0-29.9 kg/m<sup>2</sup></td>
                    <td align="center" valign="top" rowspan="1" colspan="1">59 (35)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">42 (35)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">17 (34)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">≥30.0 kg/m<sup>2</sup></td>
                    <td align="center" valign="top" rowspan="1" colspan="1">68 (40)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">49 (40)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">19 (38)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>HCT-CI</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Low Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">34 (20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">22 (18)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">12 (24)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.630</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Intermediate Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">58 (34)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">43 (36)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">15 (30)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">High Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">79 (46)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">56 (46)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">23 (46)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>WBC Count at Diagnosis</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;10 ×10<sup>3</sup>/μL</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">91 (53)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">77 (64)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14 (28)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">≥10 ×10<sup>3</sup>/μL</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">78 (46)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">43 (36)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">35 (70)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Karyotype at Diagnosis, CIBMTR Risk</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Low Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4 (3)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.004</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Intermediate Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">123 (72)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">82 (68)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">41 (82)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">High Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">23 (13)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">23 (19)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Unknown Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">17 (10)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10 (8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">7 (14)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Complex Cytogenetics (≥3 abnormalities) at Diagnosis</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">No</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">142 (83)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">94 (78)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">48 (96)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">25 (15)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">25 (21)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Other Molecular Markers</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>
                        <italic>NPM1</italic>
                      </bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td colspan="5" align="center" valign="top" rowspan="1">
                      <hr/>
                    </td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Negative</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">104 (61)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">80 (66)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">24 (48)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Positive</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">32 (19)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13 (11)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">19 (38)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Antecedent MDS/MPD</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">No</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">136 (80)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">90 (74)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">46 (92)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.009</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">35 (20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">31 (26)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4 (8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Therapy-related AML</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">No</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">160 (94)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">110 (91)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">50 (100)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.028</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">11 (6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">11 (9)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Morphologic Status at Transplant</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Complete Remission</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">136 (80)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">96 (79)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">40 (80)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.922</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Persistent Disease</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">35 (20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">25 (21)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10 (20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Time to Transplant (days)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">≤ 180</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">117 (68)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">82 (68)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">35 (70)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.775</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt; 180</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54 (32)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">39 (32)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">15 (30)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Number of Induction Cycles Before Transplant</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">≤ 2</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">134 (78)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">93 (77)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">41 (82)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.458</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt; 2</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">37 (22)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">28 (23)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">9 (18)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Total Number of Chemotherapy Cycles Before Transplant</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Median [Range]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3 [0 - 10]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3 [0 - 9]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3 [1 - 10]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.670</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <p><italic>FLT3</italic> mutational status (positive <italic>vs.</italic> negative)</p>
                <p>BMI: body mass index; HCT-CI: Hematopoietic Cell Transplantation-Specific Comorbidity Index; WBC: white blood cell; CIBMTR: Center for International Blood and Marrow Transplant Research; MDS: myelodysplastic syndrome; MPD: myeloproliferative disorder; AML: acute myelogenous leukemia</p>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="T2" position="float" orientation="portrait">
              <label>Table 2</label>
              <caption>
                <p>Transplantation Characteristics by <italic>FLT3</italic> Mutational Status</p>
              </caption>
              <table frame="void" rules="none">
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th align="center" valign="top" rowspan="1" colspan="1"><italic>FLT3</italic> Recorded</th>
                    <th align="center" valign="top" rowspan="1" colspan="1"><italic>FLT3</italic> Negative</th>
                    <th align="center" valign="top" rowspan="1" colspan="1"><italic>FLT3</italic> Positive</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                  </tr>
                  <tr>
                    <th colspan="5" align="center" valign="top" rowspan="1">
                      <hr/>
                    </th>
                  </tr>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">N (%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">N (%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">N (%)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Stem Cell Source</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Bone Marrow</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">18 (11)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13 (11)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.885</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Peripheral Blood</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">153 (89)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">108 (89)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">45 (90)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Donor-Recipient HLA and Relation</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Matched (8/8) Related</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">72 (42)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">51 (42)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">21 (42)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.305</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Matched Unrelated</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">77 (45)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">57 (47)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">20 (40)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Mismatched (&lt;8/8) Related</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2 (1)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Mismatched Unrelated</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">20 (12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">11 (9)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">9 (18)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Donor-Recipient Gender</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Male Donor, Male Recipient</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">61 (36)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">45 (37)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">16 (32)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.638</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Male Donor, Female Recipient</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">50 (29)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">36 (30)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14 (28)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Female Donor, Male Recipient</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">34 (20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">24 (20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10 (20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Female Donor, Female Recipient</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">25 (15)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">15 (12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10 (20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Donor-Recipient ABO Blood Type</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Matched</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">108 (63)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">77 (64)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">31 (62)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.055</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Anti-recipient Antibodies</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">31 (18)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">25 (21)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6 (12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Anti-donor Antibodies</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">25 (15)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">17 (14)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">8 (16)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Anti-recipient and Anti-donor Antibodies</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">7 (4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Donor-Recipient Rh Blood Type</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Matched</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">138 (81)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">100 (83)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">38 (76)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.369</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Anti-recipient Antibodies</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13 (8)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">7 (6)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6 (12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Anti-donor Antibodies</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">20 (12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14 (12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6 (12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Donor-Recipient CMV</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Recipient and Donor Negative</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">52 (30)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">38 (31)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14 (28)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.521</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Recipient Negative and Donor Positive/Unknown</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">25 (15)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">15 (12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">10 (20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Recipient Positive/Unknown and Donor Negative</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">48 (28)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">33 (27)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">15 (30)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Recipient and Donor Positive/Unknown</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">46 (27)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">35 (29)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">11 (22)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Conditioning Intensity</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Reduced Intensity</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">44 (26)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">31 (26)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13 (26)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.959</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Myeloablative</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">127 (74)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">90 (74)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">37 (74)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Use of Thymoglobulin or Alemtuzumab</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">No</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">167 (98)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">118 (98)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">49 (98)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.850</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Use of Total Body Irradiation (≥1.2Gy)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">No</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">165 (96)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">117 (97)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">48 (96)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.822</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">6 (4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4 (3)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2 (4)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>CD34 Transfused (×10<sup>6</sup> cells/kg)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Median [Range]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5.5 [1.0 - 10.6]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5.6 [1.0 - 10.6]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">5.3 [1.2 - 9.8]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.232</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>GVHD Prophylaxis</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">CSA/Tac + MMF</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">69 (40)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54 (45)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">15 (30)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.072</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">CSA/Tac + MTX</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">101 (59)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">67 (55)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">34 (68)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Tac + Sirolimus</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Length of Stay (days)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Median [Range]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">22 [17 - 97]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">22 [17 - 97]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">22 [18 - 34]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.729</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Time to Engraftment (days)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Median [Range]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">12 [4 - 23]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">12 [4 - 23]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">12 [7 - 15]</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.891</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <p><italic>FLT3</italic> mutational status (positive <italic>vs.</italic> negative)</p>
                <p>HLA: human leukocyte antigen; CMV: cytomegalovirus; Gy: gray; GVHD: graft-versus-host disease; CSA: cyclosporine; Tac: tacrolimus; MMF: mycophenolate mofetil; MTX: methotrexate</p>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="T3" position="float" orientation="landscape">
              <label>Table 3</label>
              <caption>
                <p>Univariate Analysis Results</p>
              </caption>
              <table frame="void" rules="groups">
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">N</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">3-year RR</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">1-year aGVHD (Grades 2–4)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">1-year cGVHD</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">3-year NRM</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">3-year DFS</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">3-year Overall Survival</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>All <italic>FLT3</italic> Tested</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">171</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">45%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">33%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">49%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">16%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">39%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">45%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Age</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;60 years</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">117</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">45%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.664</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">31%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.780</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">46%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.542</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.514</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">41%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.957</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">46%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.544</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">≥60 years</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">44%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">35%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">53%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">19%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">37%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">42%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>HCT-CI</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Low Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">34</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">31%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.033</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">36%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.553</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.398</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">14%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.114</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">55%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.139</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">58%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.303</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Intermediate Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">58</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">37%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">37%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">45%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">27%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">37%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">42%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">High Risk</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">79</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">56%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">28%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">49%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">10%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">34%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">42%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>WBC Count at Diagnosis</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt;10 ×10<sup>3</sup>/μL</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">91</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">43%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.315</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">34%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.996</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.045</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">17%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.707</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">40%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.425</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">47%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.801</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">≥10 ×10<sup>3</sup>/μL</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">78</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">46%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">33%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">41%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">16%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">38%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">41%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Karyotype at Diagnosis, CIBMTR Risk</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Low</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.007</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.222</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">67%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.536</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.284</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">100%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">100%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Intermediate</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">123</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">40%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">32%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">51%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">15%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">45%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">49%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">High</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">23</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">73%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">37%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">35%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">14%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">13%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">25%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Unknown</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">17</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">46%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">47%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">44%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">34%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">19%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">29%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Complex Cytogenetics (≥3 abnormalities) at Diagnosis</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">No</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">142</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">39%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">34%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.924</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">51%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.527</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">17%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.669</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">44%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">48%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">25</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">76%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">34%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">37%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">13%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">11%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">28%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Molecular Markers Prior to Transplant</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>
                        <italic>FLT3</italic>
                      </bold>
                      <hr/>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Negative</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">121</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">37%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">34%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.715</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.025</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">21%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.012</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">41%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.065</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">48%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.334</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Positive</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">50</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">63%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">30%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">36%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">4%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">32%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">38%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>
                        <italic>NPM1</italic>
                      </bold>
                      <hr/>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Negative</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">104</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">40%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.525</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">32%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.965</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">52%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.095</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">18%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.584</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">42%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.801</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">47%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.776</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Positive</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">32</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">44%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">32%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">39%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">16%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">40%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">42%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Conditioning Intensity</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Reduced Intensity</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">44</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">53%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.130</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">43%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.156</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">48%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.937</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">12%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.293</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">35%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.476</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">41%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.431</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Myeloablative</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">127</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">41%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">29%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">49%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">17%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">41%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">46%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Use of Thymoglobulin or Alemtuzumab</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">No</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">167</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">45%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.186</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">33%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.205</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">48%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.492</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">16%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.227</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">39%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.553</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">45%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.748</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Yes</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">0%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">67%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">33%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">67%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">67%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Time to Transplant (days)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">≤ 180</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">117</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">47%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.347</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">35%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.459</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">49%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.492</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">13%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.152</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">40%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.978</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">49%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.343</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt; 180</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">54</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">40%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">28%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">47%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">22%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">37%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">36%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Number of Induction Cycles Before Transplant</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">≤ 2</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">134</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">43%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.181</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">33%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.704</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">51%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.363</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">12%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.020</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">46%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.002</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">52%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt; 2</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">37</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">53%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">32%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">41%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">32%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">15%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                    <td align="center" valign="top" rowspan="1" colspan="1">19%</td>
                    <td align="center" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <p><italic>FLT3</italic> mutational status (positive <italic>vs.</italic> negative)</p>
                <p>HCT-CI: Hematopoietic Cell Transplantation-Specific Comorbidity Index; WBC: white blood cell; CIBMTR: Center for International Blood and Marrow Transplant Research; RR: relapse risk; aGVHD: acute graft-versus-host disease; cGVHD: chronic graft-versus-host disease; NRM: non-relapse mortality; DFS: disease-free survival</p>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="T4" position="float" orientation="landscape">
              <label>Table 4</label>
              <caption>
                <p>Bivariate Analysis Results</p>
              </caption>
              <table frame="void" rules="groups">
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th colspan="2" align="center" valign="top" rowspan="1">3-year RR<hr/></th>
                    <th colspan="2" align="center" valign="top" rowspan="1">1-year cGVHD<hr/></th>
                    <th colspan="2" align="center" valign="top" rowspan="1">3-year NRM<hr/></th>
                    <th colspan="2" align="center" valign="top" rowspan="1">3-year DFS<hr/></th>
                    <th colspan="2" align="center" valign="top" rowspan="1">3-year Overall Survival<hr/></th>
                  </tr>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold><italic>FLT3</italic> (Positive <italic>vs.</italic> Negative)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.25 (1.40,3.61)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.55 (0.32,0.95)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.031</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.20 (0.05,0.86)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.031</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.49 (0.97,2.29)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.066</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.26 (0.80,1.98)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.316</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Age (≥60 <italic>vs.</italic> &lt;60 years)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.57,1.52)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.770</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.19 (0.76,1.85)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.450</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.24 (0.55,2.81)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.610</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.65,1.55)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.981</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.16 (0.74,1.82)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.507</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold><italic>FLT3</italic> (Positive <italic>vs.</italic> Negative)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3.65 (2.11,6.33)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.44 (0.25,0.78)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.005</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.19 (0.04,0.81)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.025</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.06 (1.30,3.27)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.002</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.69 (1.04,2.75)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.036</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Karyotype at Diagnosis, CIBMTR Risk (High <italic>vs.</italic> Other)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">4.22 (2.32,7.67)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.52 (0.23,1.19)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.120</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.64 (0.19,2.20)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.480</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.97 (1.72,5.12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.72 (1.55,4.77)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold><italic>FLT3</italic> (Positive <italic>vs.</italic> Negative)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.90 (1.68,5.02)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.69 (0.37,1.29)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.250</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.20 (0.04,0.89)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.034</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.75 (1.06,2.89)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.028</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.37 (0.81,2.34)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.245</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold><italic>NPM1</italic> (Positive <italic>vs.</italic> Negative)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.86 (0.44,1.69)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.660</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.68 (0.35,1.32)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.250</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.19 (0.40,3.55)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.760</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.89 (0.50,1.57)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.682</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.97 (0.53,1.76)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.921</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold><italic>FLT3</italic> (Positive <italic>vs.</italic> Negative)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.25 (1.39,3.63)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.53 (0.31,0.92)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.023</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.21 (0.05,0.89)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.035</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.46 (0.95,2.24)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.081</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.27 (0.81,2.00)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.293</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Number of Induction Cycles (&gt;2 <italic>vs.</italic> ≤2)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.43 (0.82,2.50)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.210</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.65 (0.34,1.23)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.190</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.30 (1.02,5.21)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.045</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.99 (1.27,3.12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.003</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.29 (1.44,3.65)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold><italic>FLT3</italic> (Positive <italic>vs.</italic> Negative)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.23 (1.39,3.56)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.55 (0.32,0.94)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.028</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.19 (0.04,0.84)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.029</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.49 (0.97,2.28)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.067</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.28 (0.81,2.02)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.284</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>HCT-CI (High <italic>vs.</italic> Other)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.83 (1.13,2.95)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.013</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.02 (0.65,1.59)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.930</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.51 (0.22,1.18)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.120</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.37 (0.91,2.04)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.130</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.31 (0.86,2.00)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.214</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold><italic>FLT3</italic> (Positive <italic>vs.</italic> Negative)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.32 (1.44,3.75)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.55 (0.32,0.94)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.028</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.20 (0.05,0.84)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.028</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.52 (0.99,2.33)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.057</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.27 (0.81,1.99)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.307</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Conditioning Intensity (Myeloablative <italic>vs.</italic> Reduced)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.64 (0.39,1.04)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.074</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.91 (0.57,1.46)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.700</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.62 (0.63,4.16)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.320</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.83 (0.53,1.28)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.392</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.52,1.30)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.393</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold><italic>FLT3</italic> (Positive <italic>vs.</italic> Negative)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.31 (1.48,3.62)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.55 (0.32,0.94)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.029</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.19 (0.04,0.84)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.029</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.49 (0.97,2.28)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.069</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.25 (0.80,1.97)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.332</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Morphologic Status (PD <italic>vs.</italic> CR)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.09 (1.34,3.26)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.65 (0.33,1.29)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.220</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.22 (0.93,5.28)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.071</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.65 (1.71,4.12)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.45 (1.55,3.88)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <p><italic>FLT3</italic> mutational status (positive <italic>vs.</italic> negative)</p>
                <p>CIBMTR: Center for International Blood and Marrow Transplant Research; HCT-CI: Hematopoietic Cell Transplantation-Specific Comorbidity Index; PD: persistent disease; CR: complete remission (morphologic); RR: relapse risk; cGVHD: chronic graft-versus-host disease; NRM: non-relapse mortality; DFS: disease-free survival; CI: confidence interval</p>
                <p>Hazard ratios &gt;1 indicate greater hazard for poor outcome (i.e., increased RR, cGVHD, and NRM and inferior DFS and overall survival)</p>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap id="T5" position="float" orientation="landscape">
              <label>Table 5</label>
              <caption>
                <p>Multivariate Analysis Results</p>
              </caption>
              <table frame="void" rules="groups">
                <thead>
                  <tr content-type="background-color:#CCCCCC">
                    <th align="left" valign="top" rowspan="1" colspan="1">N=167<sup><xref ref-type="table-fn" rid="TFN1">†</xref></sup></th>
                    <th colspan="2" align="center" valign="top" rowspan="1">3-year RR<hr/></th>
                    <th colspan="2" align="center" valign="top" rowspan="1">1-year cGVHD<hr/></th>
                    <th colspan="2" align="center" valign="top" rowspan="1">3-year NRM<hr/></th>
                    <th colspan="2" align="center" valign="top" rowspan="1">3-year DFS<hr/></th>
                    <th colspan="2" align="center" valign="top" rowspan="1">3-year Overall Survival<hr/></th>
                  </tr>
                  <tr content-type="background-color:#CCCCCC">
                    <th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th>
                    <th align="center" valign="top" rowspan="1" colspan="1">P</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold><italic>FLT3</italic> (Positive <italic>vs.</italic> Negative)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">3.63 (2.13,6.19)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.44 (0.25,0.78)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.005</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.21 (0.05,0.92)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.038</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.05 (1.29,3.27)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.003</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.92 (1.14,3.24)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.014</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Age (≥60 <italic>vs.</italic> &lt;60)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.64 (0.39,1.06)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.081</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Karyotype at Diagnosis, CIBMTR Risk (High <italic>vs.</italic> Other)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.97 (1.52,5.77)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.52 (0.23,1.19)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.120</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.35 (1.34,4.10)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.003</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.93 (1.08,3.48)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.028</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Number of Induction Cycles (&gt;2 <italic>vs.</italic> ≤2)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.98 (0.90,4.34)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.089</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.73 (1.07,2.78)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.025</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.87 (1.14,3.09)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.014</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>HCT-CI (High <italic>vs.</italic> Other)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.71 (1.04,2.79)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.034</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.49 (0.21,1.14)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.098</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Conditioning Intensity (Myeloablative <italic>vs.</italic> Reduced)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.39 (0.21,0.72)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.003</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.57 (0.35,0.95)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.032</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.55 (0.33,0.94)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.029</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">
                      <bold>Morphologic Status (PD <italic>vs.</italic> CR)</bold>
                    </td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.61 (1.44,4.74)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.002</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">1.98 (0.88,4.47)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.100</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.52 (1.51,4.21)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">2.15 (1.23,3.78)</td>
                    <td align="center" valign="top" rowspan="1" colspan="1">0.008</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <p><italic>FLT3</italic> mutational status (positive <italic>vs.</italic> negative)</p>
                <p>CIBMTR: Center for International Blood and Marrow Transplant Research; HCT-CI: Hematopoietic Cell Transplantation-Specific Comorbidity Index; PD: persistent disease; CR: complete remission (morphologic); RR: relapse risk; cGVHD: chronic graft-versus-host disease; NRM: non-relapse mortality; DFS: disease-free survival; CI: confidence interval; N/A: not applicable (addition of characteristic did not improve fit of the multivariate model)</p>
                <p>Hazard ratios &gt;1 indicate greater hazard for poor outcome (i.e., increased RR, cGVHD, and NRM and inferior DFS and overall survival)</p>
                <fn id="TFN1">
                  <label>†</label>
                  <p id="P34">Data were available for all characteristics included in the multivariate model for 167 of 171 patients with <italic>FLT3</italic> mutational status recorded.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
